<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muhammad Dedy Pratama</style></author><author><style face="normal" font="default" size="100%">Budi Baktijasa Dharmadjati</style></author><author><style face="normal" font="default" size="100%">Muhammad Rafdi Amadis</style></author><author><style face="normal" font="default" size="100%">Ahmad Faisal Dwi Raharja</style></author><author><style face="normal" font="default" size="100%">Muhammad Ramadhan</style></author><author><style face="normal" font="default" size="100%">Dwika Rasyid Firmanda</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Successful Intrapericardial Fibrinolysis on Acute Recurrent Purulent Pericarditis with Impending Cardiac Tamponade during Pandemic Situation: A Rare Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Intrapericardial fibrinolysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Purulent pericarditis</style></keyword><keyword><style  face="normal" font="default" size="100%">Rare Case Report</style></keyword><keyword><style  face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">1033-1036</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Acute recurrent purulent pericarditis is an uncommon pericardium infection that can be life-threatening due to pus production, leading to cardiac tamponade. &lt;strong&gt;Case presentation:&lt;/strong&gt; We report a 36-year-old man referring to our hospital with impending cardiac tamponade who needed urgent pericardiocentesis. The patient's complaints were worsening dyspnea and palpitations in the last two days. The patient had been hospitalized for the same complaint and had pericardiocentesis due to cardiac tamponade approximately three weeks earlier. Physical exam, ECG, and CXR suggest impending cardiac tamponade. Echocardiography indicated massive right and left pericardial effusion and right atrial collapse. The Covid-19 screening test was positive; however, RT-PCR revealed a negative result. The patient was diagnosed with recurrent acute purulent pericarditis with impending cardiac tamponade requiring urgent pericardiocentesis. After the procedure, 1.5 million units of intrapericardial fibrinolytic were administered to patients. His improved hemodynamic and clinical symptoms indicate a successful procedure. &lt;strong&gt;Conclusion: &lt;/strong&gt;This case highlights the challenges of managing an acute recurrent purulent pericarditis patient due to &lt;em&gt;Staphylococcus A&lt;/em&gt;. infection in the current pandemic era, including distinguishing it from other contagious diseases due to nonspecific dyspnea, limited therapeutic options, and the effectiveness of intrapericardial fibrinolytic in improving the overall patient conditions, and reducing the mortality rate.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><section><style face="normal" font="default" size="100%">1033</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muhammad Dedy Pratama, Budi Baktijasa Dharmadjati*, Muhammad Rafdi Amadis, Ahmad Faisal Dwi Raharja, Muhammad Ramadhan, Dwika Rasyid Firmanda&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Department of Cardiology and Vascular Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yudi Her Oktaviono</style></author><author><style face="normal" font="default" size="100%">Muhammad Rafdi Amadis</style></author><author><style face="normal" font="default" size="100%">Makhyan Jibril Al-Farabi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">High Dose Allicin with Vitamin C Improves EPCs Migration from the Patient with Coronary Artery Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Allicin</style></keyword><keyword><style  face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelial Progenitor</style></keyword><keyword><style  face="normal" font="default" size="100%">Migration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">232-235</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Endothelial Progenitor Cells (EPCs) have an important role in endothelial dysfunction repairment through neovasculogenesis and cardiac myocytes regeneration. However, EPCs migration is greatly reduced in the patient with Coronary Artery Disease (CAD). Allicin and Vitamin C are hypothesized to improve EPCs migration due to its antioxidant properties. &lt;strong&gt;Objective:&lt;/strong&gt; To investigate the effect of Allicin and its combination with Vitamin C in EPCs migration of CAD patients. &lt;strong&gt;Material and Method:&lt;/strong&gt; Mononuclear cells were isolated from CAD patients and cultured on fibronectin-coated plates with colony-forming unit Hill medium. The cells were divided into untreated (control), Allicin treatment (dose 100 mcg/ml, 200 mcg/ml, 400 mcg/ ml), and each dose of Allicin combined with 250 mcg/mL of Vitamin C. EPCs migration was assessed with Transwell Migration Assay Kit and evaluated by using statistical tests. &lt;strong&gt;Results: &lt;/strong&gt;This research shows that EPC migration was significantly higher in the treatment. Allicin at all dose (dose 100 mcg/ml, 200 mcg/ml, 400 mcg/ml) and its combination with 250 mcg/mL of vitamin C compared to untreated group (&lt;em&gt;p&lt;/em&gt;&amp;lt;0.05). Allicin increase EPCs migration in a dosedependent manner. However, the only combination of 400 mcg/ml Allicin with 250 mcg/mL of vitamin C which has significantly higher EPCs migration compared to Allicin treatment alone. &lt;strong&gt;Conclusion: &lt;/strong&gt;Allicin improves EPCs migration in a dose-dependent manner. Improvement of the migration only observed on the Allicin dose 400 mcg/ml with Vitamin C.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">232</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Yudi Her Oktaviono&lt;sup&gt;1,&lt;/sup&gt;*, Muhammad Rafdi Amadis&lt;sup&gt;1&lt;/sup&gt;, Makhyan Jibril Al-Farabi&lt;sup&gt;1,2&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Prof Moestopo Street 6-8, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;School of Management, Healthcare Entrepreneurship Division, University College London, Gower St, Bloomsbury, WC1E 6BT London, UK.&lt;/p&gt;
</style></auth-address></record></records></xml>